Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Deferred Taxes (2020 - 2025)

Historic Deferred Taxes for Neurocrine Biosciences (NBIX) over the last 5 years, with Q4 2025 value amounting to $48.2 million.

  • Neurocrine Biosciences' Deferred Taxes rose 25399.36% to $48.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $165.4 million, marking a year-over-year increase of 23436.23%. This contributed to the annual value of $165.4 million for FY2025, which is 23436.23% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Deferred Taxes of $48.2 million as of Q4 2025, which was up 25399.36% from $168.3 million recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Deferred Taxes registered a high of $168.3 million during Q3 2025, and its lowest value of -$41.5 million during Q2 2023.
  • Over the past 4 years, Neurocrine Biosciences' median Deferred Taxes value was -$15.6 million (recorded in 2024), while the average stood at -$1.6 million.
  • As far as peak fluctuations go, Neurocrine Biosciences' Deferred Taxes tumbled by 73095.24% in 2024, and later soared by 58223.5% in 2025.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' Deferred Taxes stood at -$6.2 million in 2021, then skyrocketed by 432.26% to $20.6 million in 2023, then crashed by 251.94% to -$31.3 million in 2024, then skyrocketed by 253.99% to $48.2 million in 2025.
  • Its Deferred Taxes stands at $48.2 million for Q4 2025, versus $168.3 million for Q3 2025 and -$37.4 million for Q2 2025.